Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis

Showing results (201-210 of 251) with videos related to

Pageof 26
Sort By:
Cancer|April 3, 2015
Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man studyRenata Pasqualini, Randall E Millikan, Dawn R Christianson, et al.
Cancer|March 29, 2016
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerShi-Ming Tu, Mehmet Asim Bilen, Kenneth R Hess, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2024
Body composition as a determinant of the therapeutic index with androgen signaling inhibitionAndrew W Hahn, Rebecca S Tidwell, Patrick G Pilie, et al.
Cell Reports|April 6, 2022
Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasisHyunho Han, Yan Wang, Josue Curto, et al.
Cancer Research|January 30, 2014
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancerJohn R Prensner, Wei Chen, Matthew K Iyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) SeriesNicolas Anselmino, Estefania Labanca, Peter D A Shepherd, et al.
Science Translational Medicine|September 5, 2014
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesXinhai Wan, Paul G Corn, Jun Yang, et al.
Pageof 26

Showing results (201-210 of 251) with videos related to

Sort By:
Pageof 26
Cancer|April 3, 2015
Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man studyRenata Pasqualini, Randall E Millikan, Dawn R Christianson, et al.
Cancer|March 29, 2016
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerShi-Ming Tu, Mehmet Asim Bilen, Kenneth R Hess, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2024
Body composition as a determinant of the therapeutic index with androgen signaling inhibitionAndrew W Hahn, Rebecca S Tidwell, Patrick G Pilie, et al.
Cell Reports|April 6, 2022
Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasisHyunho Han, Yan Wang, Josue Curto, et al.
Cancer Research|January 30, 2014
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancerJohn R Prensner, Wei Chen, Matthew K Iyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) SeriesNicolas Anselmino, Estefania Labanca, Peter D A Shepherd, et al.
Science Translational Medicine|September 5, 2014
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesXinhai Wan, Paul G Corn, Jun Yang, et al.
Pageof 26